1.IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C.
Fattovich G, Covolo L, Bibert S, Askarieh G, Lagging M, Clément S, Malerba G, Pasino M, Guido M, Puoti M, Gaeta GB, Santantonio T, Raimondo G, Bruno R, Bochud PY, Donato F, Negro F; on behalf of the ITAHEC Study Group.
Aliment Pharmacol Ther. 2011 Mar 28. doi: 10.1111/j.1365-2036.2011.04635.x. [Epub ahead of print]
PMID:21443535[PubMed - as supplied by publisher]
Related citations
2.IL28B single nucleotide polymorphisms in the treatment of hepatitis C.
Lange CM, Zeuzem S.
J Hepatol. 2011 Mar 24. [Epub ahead of print]
PMID:21440591[PubMed - as supplied by publisher]
Related citations
3.High-Dose Pegylated Interferon Alfa and Ribavirin in Non-responder Hepatitis C Patients and Relationship with IL28B Genotype (SYREN Trial).Chevaliez S, Hézode C, Soulier A, Costes B, Bouvier-Alias M, Rouanet S, Foucher J, Bronowicki JP, Tran A, Rosa I, Mathurin P, Alric L, Leroy V, Couzigou P, Mallat A, Charaf-Eddine M, Babany G, Pawlotsky JM.
Gastroenterology. 2011 Mar 23. [Epub ahead of print]
PMID:21439960[PubMed - as supplied by publisher]
Related citations
4.[Treatment of hepatitis C virus in HIV-positive patients.]
Mallolas Masferrer J, Martínez-Rebollar M, Laguno Centeno M.
Gastroenterol Hepatol. 2011 Mar 22. [Epub ahead of print] Spanish.
PMID:21435743[PubMed - as supplied by publisher]
Related citations
Nat Rev Gastroenterol Hepatol. 2011 Mar 22. [Epub ahead of print]
PMID:21423258[PubMed - as supplied by publisher]
Related citations
6.[Genetics and hepatitis C treatment: towards a personalized treatment?]
Lens García S, Coto-Llerena M, Pérez Del Pulgar Gallart S, Forns Bernhardt X.
Gastroenterol Hepatol. 2011 Mar 18. [Epub ahead of print] Spanish.
PMID:21420759[PubMed - as supplied by publisher]
Related citations
7.Genetic variation in IL28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV infected children.
Ruiz-Extremera A, Muñoz-Gámez J, Salmerón-Ruiz MA, de Rueda PM, Quiles-Pérez R, Gila-Medina A, Casado J, Martín AB, Sanjuan-Nuñez L, Carazo A, Pavón EJ, Ocete-Hita E, León J, Salmerón J.
Hepatology. 2011 Mar 16. doi: 10.1002/hep.24298. [Epub ahead of print]
PMID:21413051[PubMed - as supplied by publisher]
Related citations
8.Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection.
Dring MM, Morrison MH, McSharry BP, Guinan KJ, Hagan R; Irish HCV Research Consortium, O'Farrelly C, Gardiner CM.
Proc Natl Acad Sci U S A. 2011 Mar 14. [Epub ahead of print]
PMID:21402922[PubMed - as supplied by publisher]
Related citations
9.Portal Pressure Predicts Outcome and Safety of Antiviral Therapy in Cirrhotic Patients with HCV infection.
Reiberger T, Rutter K, Ferlitsch A, Payer BA, Hofer H, Beinhardt S, Kundi M, Ferenci P, Gangl A, Trauner M, Peck-Radosavljevic M.
Clin Gastroenterol Hepatol. 2011 Mar 10. [Epub ahead of print]
PMID:21397726[PubMed - as supplied by publisher]
Related citations
10.Response Prediction in Chronic Hepatitis C by Assessment of IP-10 and IL28B-Related Single Nucleotide Polymorphisms.
Lagging M, Askarieh G, Negro F, Bibert S, Söderholm J, Westin J, Lindh M, Romero A, Missale G, Ferrari C, Neumann AU, Pawlotsky JM, Haagmans BL, Zeuzem S, Bochud PY, Hellstrand K; for the DITTO-HCV Study Group.
PLoS One. 2011 Feb 24;6(2):e17232.
PMID:21390311[PubMed - as supplied by publisher] Free PMC Article
Free full text Related citations
11.Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients.
Labarga P, Soriano V, Caruz A, Poveda E, Di Lello F, Hernandez-Quero J, Moreno S, Bernal E, Miró JM, Leal M, Gutierrez F, Portilla J, Pineda JA; on behalf of CoRIS.
AIDS. 2011 Mar 27;25(6):761-766.
PMID:21378537[PubMed - as supplied by publisher]
Related citations
12.Coffee Consumption is Associated with Response to Peginterferon and Ribavirin Therapy in Patients with Chronic Hepatitis C.
Freedman ND, Curto TM, Lindsay KL, Wright EC, Sinha R, Everhart JE; HALT-C Trial Group.
Gastroenterology. 2011 Mar 1. [Epub ahead of print]
PMID:21376050[PubMed - as supplied by publisher]
Related citations
13.IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection.
Moghaddam A, Melum E, Reinton N, Ring-Larsen H, Verbaan H, Bjøro K, Dalgard O.
PMID:21374656[PubMed - in process]
Related citations
14.Estimating the net contribution of IL28B variation to spontaneous hepatitis C virus clearance.
di Iulio J, Ciuffi A, Fitzmaurice K, Kelleher D, Rotger M, Fellay J, Martinez R, Pulit S, Furrer H, Günthard HF, Battegay M, Bernasconi E, Schmid P, Hirschel B, Barnes E, Klenerman P, Telenti A, Rauch A; the Swiss HIV Cohort Study.
Hepatology. 2011 Feb 28. doi: 10.1002/hep.24263. [Epub ahead of print]
PMID:21360716[PubMed - as supplied by publisher]
Related citations
15.Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b.Sakamoto N, Nakagawa M, Tanaka Y, Sekine-Osajima Y, Ueyama M, Kurosaki M, Nishida N, Tamori A, Yuki NS, Itsui Y, Azuma S, Kakinuma S, Hige S, Itoh Y, Tanaka E, Hiasa Y, Izumi N, Tokunaga K, Mizokami M, Watanabe M; the Ochanomizu-Liver Conference Study Group.
J Med Virol. 2011 May;83(5):871-878. doi: 10.1002/jmv.22038. Epub 2011 Feb 25.
PMID:21360545[PubMed - as supplied by publisher]
Related citations
16.HCV-GenoFibrotest: A combination of viral, liver and genomic (IL28b, ITPA, UGT1A1) biomarkers for predicting treatment response in patients with chronic hepatitis C.Costa JM, Telehin D, Munteanu M, Kobryn T, Ngo Y, Thibault V, Joseph M, Ratziu V, Benhamou Y, Koz'ko V, Dubins'ka G, Poveda JD, Poynard T.
Clin Res Hepatol Gastroenterol. 2011 Feb 25. [Epub ahead of print]
PMID:21354889[PubMed - as supplied by publisher]
Related citations
17.IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C.
Bochud PY, Bibert S, Negro F, Haagmans B, Soulier A, Ferrari C, Missale G, Zeuzem S, Pawlotsky JM, Schalm S, Hellstrand K, Neumann AU, Lagging M; the DITTO-HCV study group.
J Hepatol. 2011 Feb 24. [Epub ahead of print]
PMID:21354446[PubMed - as supplied by publisher]
Related citations
18.IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-α plus ribavirin therapy in Taiwanese chronic HCV infection.
Chen JY, Lin CY, Wang CM, Lin YT, Kuo SN, Shiu CF, Chang SW, Wu J, Sheen IS.
Genes Immun. 2011 Feb 24. [Epub ahead of print]
PMID:21346780[PubMed - as supplied by publisher]
Related citations
19.Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics.Tavis JE, Donlin MJ, Aurora R, Fan X, Di Bisceglie AM.
Genome Med. 2011 Feb 8;3(2):8. [Epub ahead of print]
PMID:21345258[PubMed - as supplied by publisher]
Related citations
20.Amino Acid Substitution in HCV Core Region and Genetic Variation near the IL28B Gene Affect Viral Dynamics during Telaprevir, Peginterferon and Ribavirin Treatment.Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y, Kumada H.
Intervirology. 2011 Feb 16. [Epub ahead of print]
PMID:21325786[PubMed - as supplied by publisher]
Related citations